Hoskuld
4 minutes ago
If another huge pharmaceutical company is marketing and selling then...yes. Or if you have head to head data - a KarXT arm that is shown to be less effective in the same trial than 3-71.
But, all things being equal, when a big marketing machine launches first in class SOC therapy,